862011-06-1Relevant academic research and scientific papers
2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4
Knoepfel, Thomas,Furet, Pascal,Mah, Robert,Buschmann, Nicole,Leblanc, Catherine,Ripoche, Sebastien,Graus-Porta, Diana,Wartmann, Markus,Galuba, Inga,Fairhurst, Robin A.
, p. 215 - 220 (2018)
As part of a project to identify FGFR4 selective inhibitors, scaffold morphing of a 2-formylquinoline amide hit identified series of 2-formylpyridine ureas (2-FPUs) with improved potency and physicochemical properties. In particular, tetrahydronaphthyridi
FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS
-
Page/Page column 83, (2016/10/11)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically activ
Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
-
Paragraph 0772; 0850, (2015/05/05)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
SPIROCYCLIC PIPERIDINE DERIVATIVES AS TRPM 8 MODULATORS
-
Page/Page column 33, (2010/10/03)
The present invention provides Transient Receptor Potential subfamily M, member 8 (TRPM8) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPM8.
Chk-1 inhibitors
-
Page/Page column 45, (2010/02/13)
This invention provides compounds and methods for treating cancer. More particularly, the invention provides compounds that inhibit Chk-1. These compounds potentiate the action of DNA-damaging agents such as chemotherapy and radiation therapy.
